Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Management and control of tuberculosis control in socially complex groups: a research programme including three RCTs›References

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

Management and control of tuberculosis control in socially complex groups: a research programme including three RCTs · References

References

CC BY 4.0 · NIHR Journals Library · approximately 16 min read

  1. WHO. WHO Guidelines for Treatment of Drug-susceptible Tuberculosis and Patient Care (2017 Update). Geneva: WHO; 2017.
  2. Aldridge RW, Hayward AC, Hemming S, Yates SK, Ferenando G, Possas L, et al. High prevalence of latent tuberculosis and bloodborne virus infection in a homeless population. Thorax 2018;73:557–64. 10.1136/thoraxjnl-2016-20957929378859
  3. Story A, Murad S, Roberts W, Verheyen M, Hayward AC, London Tuberculosis Nurses Network. Tuberculosis in London: the importance of homelessness, problem drug use and prison. Thorax 2007;62:667–71. 10.1136/thx.2006.06540917289861
  4. Gelberg L, Panarites CJ, Morgenstern H, Leake B, Andersen RM, Koegel P. Tuberculosis skin testing among homeless adults. J Gen Intern Med 1997;12:25–33. 10.1007/s11606-006-0004-49034943
  5. Dewan PK, Grinsdale J, Liska S, Wong E, Fallstad R, Kawamura LM. Feasibility, acceptability, and cost of tuberculosis testing by whole-blood interferon-gamma assay. BMC Infect Dis 2006;6:47. 10.1186/1471-2334-6-4716539718
  6. Public Health England. Tuberculosis (TB): Regional and Devolved Administration Reports. 2016. URL: www.gov.uk/government/publications/tuberculosis-tb-regional-reports (accessed 3 May 2019).
  7. Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res 2011;133:257–66.21441678
  8. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011;365:2155–66. 10.1056/NEJMoa110487522150035
  9. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935–52. 10.1164/rccm.200510-1666ST17021358
  10. Jit M, Stagg HR, Aldridge RW, White PJ, Abubakar I, Find and Treat Evaluation Team. Dedicated outreach service for hard to reach patients with tuberculosis in London: observational study and economic evaluation. BMJ 2011;343:d5376. 10.1136/bmj.d537622067473
  11. NICE. Clinical Diagnosis and Management of Tuberculosis and Measures for its Prevention and Control. 2016. URL: www.nice.org.uk/guidance/ng33 (accessed 3 May 2019).
  12. NICE. Tuberculosis: Identification and Management in Under-served Groups. Public Health Guideline (PH37). 2012. URL: www.nice.org.uk/guidance/ph37 (accessed 3 May 2019).
  13. Qiagen. Interpretation Criteria for QuantiFERON-TB Gold Plus (Table 4). 2016. URL: www.quantiferon.com/wp-content/uploads/2017/04/English_QFTPlus_ELISA_R04_022016.pdf (accessed 3 May 2019).
  14. Komurian-Pradel F, Perret M, Deiman B, Sodoyer M, Lotteau V, Paranhos-Baccalà G, André P. Strand specific quantitative real-time PCR to study replication of hepatitis C virus genome. J Virol Methods 2004;116:103–6. 10.1016/j.jviromet.2003.10.00414715313
  15. Lobato MN, Leary LS, Simone PM. Treatment for latent TB in correctional facilities: a challenge for TB elimination. Am J Prev Med 2003;24:249–53. 10.1016/S0749-3797(02)00583-412657343
  16. Greveson K, Goodhand J, Capocci S, Woodward S, Murray C, Cropley I, et al. Yield and cost effectiveness of mycobacterial infection detection using a simple IGRA-based protocol in UK subjects with inflammatory bowel disease suitable for anti-TNFα therapy. J Crohns Colitis 2013;7:412–18. 10.1016/j.crohns.2012.08.01023009739
  17. Public Health England. Hepatitis C in England and the UK. URL: www.gov.uk/government/publications/hepatitis-c-in-the-uk (accessed 3 May 2019).
  18. Homeless Link. Health Needs Audit – Explore the Data. URL: www.homeless.org.uk/facts/homelessness-in-numbers/health-needs-audit-explore-data (accessed 3 May 2019).
  19. Laurenti P, Bruno S, Quaranta G, La Torre G, Cairo AG, Nardella P, et al. Tuberculosis in sheltered homeless population of Rome: an integrated model of recruitment for risk management. Scientific World Journal 2012;2012:396302. 10.1100/2012/39630222448132
  20. Lee CH, Jeong YJ, Heo EY, Park JS, Lee JS, Lee BJ, et al. Active pulmonary tuberculosis and latent tuberculosis infection among homeless people in Seoul, South Korea: a cross-sectional study. BMC Public Health 2013;13:720. 10.1186/1471-2458-13-72023914947
  21. McAdam JM, Bucher SJ, Brickner PW, Vincent RL, Lascher S. Latent tuberculosis and active tuberculosis disease rates among the homeless, New York, New York, USA, 1992–2006. Emerging Infect Dis 2009;15:1109–11. 10.3201/eid1507.080410
  22. Tabuchi T, Takatorige T, Hirayama Y, Nakata N, Harihara S, Shimouchi A, et al. Tuberculosis infection among homeless persons and caregivers in a high-tuberculosis-prevalence area in Japan: a cross-sectional study. BMC Infect Dis 2011;11:22. 10.1186/1471-2334-11-2221255421
  23. Beijer U, Wolf A, Fazel S. Prevalence of tuberculosis, hepatitis C virus, and HIV in homeless people: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:859–70. 10.1016/S1473-3099(12)70177-922914343
  24. Sherriff LC, Mayon-White RT. A survey of hepatitis C prevalence amongst the homeless community of Oxford. J Public Health Med 2003;25:358–61. 10.1093/pubmed/fdg08814747596
  25. Story A, Aldridge RW, Gray T, Burridge S, Hayward AC. Influenza vaccination, inverse care and homelessness: cross-sectional survey of eligibility and uptake during the 2011/12 season in London. BMC Public Health 2014;14:44. 10.1186/1471-2458-14-4424433371
  26. Story A, Aldridge RW, Abubakar I, Stagg HR, Lipman M, Watson JM, Hayward AC. Active case finding for pulmonary tuberculosis using mobile digital chest radiography: an observational study. Int J Tuberc Lung Dis 2012;16:1461–7. 10.5588/ijtld.11.077322981252
  27. GOV.UK. Statutory Homelessness January to March 2016 and Homelessness Prevention and Relief 2015 to 2016: England. URL: www.gov.uk/government/statistics/statutory-homelessness-january-to-march-2016-and-homelessness-prevention-and-relief-2015-to-2016-england (accessed 3 May 2019).
  28. GOV.UK. Rough Sleeping in England: Autumn 2015. URL: www.gov.uk/government/statistics/rough-sleeping-in-england-autumn-2015 (accessed 3 May 2019).
  29. Story A. Slopes and cliffs in health inequalities: comparative morbidity of housed and homeless people. Lancet 2013;382:S93. 10.1016/S0140-6736(13)62518-0
  30. Morrison DS. Homelessness as an independent risk factor for mortality: results from a retrospective cohort study. Int J Epidemiol 2009;38:877–83. 10.1093/ije/dyp16019304988
  31. Fenton KA, Aquino GA, Dean HD. Program collaboration and service integration in the prevention and control of HIV infection, viral hepatitis, STDs, and tuberculosis in the U.S.: lessons learned from the field. Public Health Rep 2014;129(Suppl. 1):1–4. 10.1177/00333549141291S101
  32. Public Health England and NHS England. Tuberculosis (TB): Collaborative Strategy for England. URL: www.gov.uk/government/publications/collaborative-tuberculosis-strategy-for-england (accessed 3 May 2019).
  33. NICE. Identifying and Managing Tuberculosis Among Hard-to-Reach Groups. NICE Public Health Guidance 37. 2012. URL: www.nice.org.uk/guidance/ng33/evidence/appendix-n-ph37-80851860866 (accessed 16 October 2020).
  34. Aldridge RW. Homelessness and quality adjusted life years: slopes and cliffs in health inequalities a cross-sectional survey. Int J Epidemiol 2015;44:i80–1. 10.1093/ije/dyv097.295
  35. Swan D, Cullen W, Macias J, Oprea C, Story A, Surey J, et al. Hepcare Europe – bridging the gap in the treatment of hepatitis C: study protocol. Expert Rev Gastroenterol Hepatol 2018;12:303–14. 10.1080/17474124.2018.142454129300496
  36. Aldridge RW, Shaji K, Hayward AC, Abubakar I. Accuracy of probabilistic linkage using the enhanced matching system for public health and epidemiological studies. PLOS ONE 2015;10:e0136179. 10.1371/journal.pone.0136179 26302242
  37. Melendez J, Hogeweg L, Sánchez CI, Philipsen RHHM, Aldridge RW, Hayward AC, et al. Accuracy of an automated system for tuberculosis detection on chest radiographs in high-risk screening. Int J Tuberc Lung Dis 2018;22:567–71. 10.5588/ijtld.17.0492 29663963
  38. Aldridge RW, Zenner D, White PJ, Williamson EJ, Muzyamba MC, Dhavan P, et al. Tuberculosis in migrants moving from high-incidence to low-incidence countries: a population-based cohort study of 519,955 migrants screened before entry to England, Wales, and Northern Ireland. Lancet 2016;388:2510–18. 10.1016/S0140-6736(16)31008-X27742165
  39. Aisyah DN, Shallcross L, Hayward A, Aldridge RW, Hemming S, Yates S, et al. Hepatitis C among vulnerable populations: a seroprevalence study of homeless, people who inject drugs and prisoners in London. J Viral Hepat 2018;25:1260–9. 10.1111/jvh.1293629851232
  40. Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis incidence in prisons: a systematic review. PLOS Med 2010;7:e1000381. 10.1371/journal.pmed.100038121203587
  41. Ruddy MC, Davies AP, Yates MD, Yates S, Balasegaram S, Drabu Y, et al. Outbreak of isoniazid resistant tuberculosis in north London. Thorax 2004;59:279–85. 10.1136/thx.2003.01040515047945
  42. Winetsky DE, Almukhamedov O, Pulatov D, Vezhnina N, Dooronbekova A, Zhussupov B. Prevalence, risk factors and social context of active pulmonary tuberculosis among prison inmates in Tajikistan. PLOS ONE 2014;9:e86046. 10.1371/journal.pone.008604624465861
  43. Hanau-Berçot B, Grémy I, Raskine L, Bizet J, Gutierrez MC, Boyer-Mariotte S, et al. A one-year prospective study (1994–1995) for a first evaluation of tuberculosis transmission in French prisons. Int J Tuberc Lung Dis 2000;4:853–9.10985654
  44. March F, Coll P, Guerrero RA, Busquets E, Caylà JA, Prats G. Predictors of tuberculosis transmission in prisons: an analysis using conventional and molecular methods. AIDS 2000;14:525–35. 10.1097/00002030-200003310-0000810780715
  45. Williams K, Poyser J, Hopkins K. Research Summary 3/12. Accommodation, Homelessness and Reoffending of Prisoners: Results from the Surveying Prisoner Crime Reduction (SPCR) Survey. 2012. URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/278806/homelessness-reoffending-prisoners.pdf (accessed 3 May 2019).
  46. Anderson C, Story A, Brown T, Drobniewski F, Abubakar I. Tuberculosis in UK prisoners: a challenge for control. J Epidemiol Community Health 2010;64:373–6. 10.1136/jech.2009.09437520231737
  47. Department of Health and National AIDS Trust. Tackling Blood-borne Viruses in Prison. A Framework for Best Practice in the UK. 2011. URL: www.nat.org.uk/publication/tackling-blood-borne-viruses-prisons-framework-best-practice-uk (accessed 3 May 2019).
  48. Public Health England. Unlinked Anonymous HIV and Viral Hepatitis Monitoring Among PWID: 2014 Report. 2014. URL: www.gov.uk/government/publications/people-who-inject-drugs-hiv-and-viral-hepatitis-monitoring (accessed 3 May 2019).
  49. Public Health England, Health Protection Scotland, Public Health Wales and Public Health Agency. Shooting Up. Infections Among People Who Inject Drugs in the United Kingdom 2013. An Update November 2014. 2014. URL: www.gov.uk/government/publications/shooting-up-infections-among-people-who-inject-drugs-in-the-uk (accessed 3 May 2019).
  50. Tamne S, London TB Workforce. The Use of Directly Observed Therapy in Tuberculosis. A Survey by the London TB Workforce. London: London TB Workforce; 2017.
  51. Sagnelli E, Starnini G, Sagnelli C, Monarca R, Zumbo G, Pontali E, et al. Blood born viral infections, sexually transmitted diseases and latent tuberculosis in Italian prisons: a preliminary report of a large multicenter study. Eur Rev Med Pharmacol Sci 2012;16:2142–6.23280032
  52. Ritter C, Elger BS. Prevalence of positive tuberculosis skin tests during 5 years of screening in a Swiss remand prison. Int J Tuberc Lung Dis 2012;16:65–9. 10.5588/ijtld.11.015922236848
  53. Marco A, Solé N, Orcau A, Escribano M, del Baño L, Quintero S, Caylà JA. Prevalence of latent tuberculosis infection in inmates recently incarcerated in a men’s prison in Barcelona. Int J Tuberc Lung Dis 2012;16:60–4. 10.5588/ijtld.11.000722236847
  54. García-Guerrero J, Marco Mouriño A, Sáiz de la Hoya Zamácola P, Vera-Remartínez EJ, Grupo de estudio PREVALHEP de prisiones. [Multi-centre study of the prevalence of latent tuberculosis infection amongst inmates in Spanish prisons.] Rev Esp Sanid Penit 2010;12:79–85. 10.4321/S1575-06202010000300003 23128564
  55. Baillargeon J, Black SA, Leach CT, Jenson H, Pulvino J, Bradshaw P, Murray O. The infectious disease profile of Texas prison inmates. Prev Med 2004;38:607–12. 10.1016/j.ypmed.2003.11.020 15066363
  56. Cohen JA. A coefficient of agreement for nominal scales. Educ Psychol Meas 1960;20:37–46. 10.1177/001316446002000104
  57. Public Health England. Tuberculosis in the UK. 2014 Report. 2014. URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/360335/TB_Annual_report__4_0_300914.pdf (accessed 3 May 2019).
  58. Aerts A, Hauer B, Wanlin M, Veen J. Tuberculosis and tuberculosis control in European prisons. Int J Tuberc Lung Dis 2006;10:1215–23.17131779
  59. Puisis M, Feinglass J, Lidow E, Mansour M. Radiographic screening for tuberculosis in a large urban county jail. Public Health Rep 1996;111:330–4.8711100
  60. Jones TF, Schaffner W. Miniature chest radiograph screening for tuberculosis in jails: a cost-effectiveness analysis. Am J Respir Crit Care Med 2001;164:77–81. 10.1164/ajrccm.164.1.201010811435242
  61. Leung CC, Chan CK, Tam CM, Yew WW, Kam KM, Au KF, et al. Chest radiograph screening for tuberculosis in a Hong Kong prison. Int J Tuberc Lung Dis 2005;9:627–32.15971389
  62. Kazi AM, Shah SA, Jenkins CA, Shepherd BE, Vermund SH. Risk factors and prevalence of tuberculosis, human immunodeficiency virus, syphilis, hepatitis B virus, and hepatitis C virus among prisoners in Pakistan. Int J Infect Dis 2010;14(Suppl. 3):e60–6. 10.1016/j.ijid.2009.11.01220189863
  63. Verneuil L, Vidal JS, Ze Bekolo R, Vabret A, Petitjean J, Leclercq R, Leroy D. Prevalence and risk factors of the whole spectrum of sexually transmitted diseases in male incoming prisoners in France. Eur J Clin Microbiol Infect Dis 2009;28:409–13. 10.1007/s10096-008-0642-z18998176
  64. Fialho M, Messias M, Page-Shafer K, Farre L, Schmalb M, Pedral-Sampaio D, et al. Prevalence and risk of blood-borne and sexually transmitted viral infections in incarcerated youth in Salvador, Brazil: opportunity and obligation for intervention. AIDS Behav 2008;12(Suppl. 4):17–24. 10.1007/s10461-008-9409-x
  65. Solomon L, Flynn C, Muck K, Vertefeuille J. Prevalence of HIV, syphilis, hepatitis B, and hepatitis C among entrants to Maryland correctional facilities. J Urban Health 2004;81:25–37. 10.1093/jurban/jth08515047781
  66. Solé N, Marco A, Escribano M, Orcau A, Quintero S, Del Baño L, Caylà JA. [Prevalence of latent tuberculosis infection amongst immigrants entering prison.] Rev Esp Sanid Penit 2012;14:12–18. 10.1590/S1575-0620201200010000322437904
  67. Hussain H, Akhtar S, Nanan D. Prevalence of and risk factors associated with Mycobacterium tuberculosis infection in prisoners, North West Frontier Province, Pakistan. Int J Epidemiol 2003;32:794–9. 10.1093/ije/dyg247 14559752
  68. Margolis B, Al-Darraji HA, Wickersham JA, Kamarulzaman A, Altice FL. Prevalence of tuberculosis symptoms and latent tuberculous infection among prisoners in northeastern Malaysia. Int J Tuberc Lung Dis 2013;17:1538–44. 10.5588/ijtld.13.019324200265
  69. Al-Darraji HA, Kamarulzaman A, Altice FL. Latent tuberculosis infection in a Malaysian prison: implications for a comprehensive integrated control program in prisons. BMC Public Health 2014;14:22. 10.1186/1471-2458-14-2224405607
  70. Chan PC, Yang CH, Chang LY, Wang KF, Kuo YC, Lin CJ, et al. Lower prevalence of tuberculosis infection in BCG vaccinees: a cross-sectional study in adult prison inmates. Thorax 2013;68:263–8. 10.1136/thoraxjnl-2012-20220823019256
  71. Tait JM, McIntyre PG, McLeod S, Nathwani D, Dillon JF. The impact of a managed care network on attendance, follow-up and treatment at a hepatitis C specialist centre. J Viral Hepat 2010;17:698–704. 10.1111/j.1365-2893.2009.01227.x20002561
  72. Novick DM, Kreek MJ. Critical issues in the treatment of hepatitis C virus infection in methadone maintenance patients. Addiction 2008;103:905–18. 10.1111/j.1360-0443.2008.02188.x18422827
  73. Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006;101:2254–62. 10.1111/j.1572-0241.2006.00731.x17032190
  74. Aldridge RW, Hayward AC, Hemming S, Possas L, Ferenando G, Garber E, et al. Effectiveness of peer educators on the uptake of mobile X-ray tuberculosis screening at homeless hostels: a cluster randomised controlled trial. BMJ Open 2015;5:e008050. 10.1136/bmjopen-2015-008050
  75. Public Health England. Tuberculosis in the UK: 2013 Report. 2013. URL: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/325632/TB_in_the_UK.pdf (accessed 3 May 2019).
  76. de Vries G, Aldridge RW, Cayla JA, Haas WH, Sandgren A, van Hest NA, Abubakar I, Tuberculosis in European Union Big Cities Working Group. Epidemiology of tuberculosis in big cities of the European Union and European Economic Area countries. Euro Surveill 2014;19:20726. 10.2807/1560-7917.es2014.19.9.20726 24626208
  77. de Vries G, van Hest RA. From contact investigation to tuberculosis screening of drug addicts and homeless persons in Rotterdam. Eur J Public Health 2006;16:133–6. 10.1093/eurpub/cki20316230316
  78. Paquette K, Cheng MP, Kadatz MJ, Cook VJ, Chen W, Johnston JC. Chest radiography for active tuberculosis case finding in the homeless: a systematic review and meta-analysis. Int J Tuberc Lung Dis 2014;18:1231–6. 10.5588/ijtld.14.0105 25216838
  79. Webel AR, Okonsky J, Trompeta J, Holzemer WL. A systematic review of the effectiveness of peer-based interventions on health-related behaviors in adults. Am J Public Health 2010;100:247–53. 10.2105/AJPH.2008.149419 20019321
  80. Medley A, Kennedy C, O’Reilly K, Sweat M. Effectiveness of peer education interventions for HIV prevention in developing countries: a systematic review and meta-analysis. AIDS Educ Prev 2009;21:181–206. 10.1521/aeap.2009.21.3.181 19519235
  81. Croft LA, Hayward AC, Story A. Tuberculosis peer educators: personal experiences of working with socially excluded communities in London. Int J Tuberc Lung Dis 2013;17(Suppl. 10):36–40. 10.5588/ijtld.13.0309 24020600
  82. Groundswell. Groundswell. 2014. URL: www.groundswell.org.uk/ (accessed 3 May 2019).
  83. Gliddon HD, Shorten RJ, Hayward AC, Story A. A sputum sample processing method for community and mobile tuberculosis diagnosis using the Xpert MTB/RIF assay. ERJ Open Res 2019;5:00165–2018. 10.1183/23120541.00165-2018 30723725
  84. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010;363:1005–15. 10.1056/NEJMoa0907847 20825313
  85. Banada PP, Sivasubramani SK, Blakemore R, Boehme C, Perkins MD, Fennelly K, Alland D. Containment of bioaerosol infection risk by the Xpert MTB/RIF assay and its applicability to point-of-care settings. J Clin Microbiol 2010;48:3551–7. 10.1128/JCM.01053-10 20720033
  86. Story A, Aldridge RW, Smith CM, Garber E, Hall J, Ferenando G, et al. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet 2019;393:1216–24. 10.1016/S0140-6736(18)32993-330799062
  87. Bayer R, Wilkinson D. Directly observed therapy for tuberculosis: history of an idea. Lancet 1995;345:1545–8. 10.1016/S0140-6736(95)91090-57677849
  88. WHO TB Control Programme. WHO Report on the Tuberculosis Epidemic: Stop TB at the Source. Geneva: WHO; 1996.
  89. Fox W. The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle 1958;39:269–74. 10.1016/s0041-3879(58)80088-4 13592910
  90. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016;63:e147–95. 10.1093/cid/ciw37627516382
  91. Story A, Garfein RS, Hayward A, Rusovich V, Dadu A, Soltan V, et al. Monitoring therapy compliance of tuberculosis patients by using video-enabled electronic devices. Emerging Infect Dis 2016;22:538–40. 10.3201/eid2203.151620
  92. Krueger K, Ruby D, Cooley P, Montoya B, Exarchos A, Djojonegoro BM, Field K. Videophone utilization as an alternative to directly observed therapy for tuberculosis. Int J Tuberc Lung Dis 2010;14:779–81.20487619
  93. Wade VA, Karnon J, Eliott JA, Hiller JE. Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation. PLOS ONE 2012;7:e50155. 10.1371/journal.pone.005015523226243
  94. Mirsaeidi M, Farshidpour M, Banks-Tripp D, Hashmi S, Kujoth C, Schraufnagel D. Video directly observed therapy for treatment of tuberculosis is patient-oriented and cost-effective. Eur Respir J 2015;46:871–4. 10.1183/09031936.00011015 25792632
  95. Holzschuh EL, Province S, Johnson K, Walls C, Shemwell C, Martin G, et al. Use of video directly observed therapy for treatment of latent tuberculosis infection - Johnson County, Kansas, 2015. MMWR Morb Mortal Wkly Rep 2017;66:387–9. 10.15585/mmwr.mm6614a328406884
  96. Gassanov MA, Feldman LJ, Sebastian A, Kraguljac MJ, Rea E, Yaffe B. The use of videophone for directly observed therapy for the treatment of tuberculosis. Can J Public Health 2013;104:e272. 10.17269/cjph.104.386923823897
  97. Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Enhancing management of tuberculosis treatment with video directly observed therapy in New York City. Int J Tuberc Lung Dis 2016;20:588–93. 10.5588/ijtld.15.0738 27084810
  98. Garfein RS, Collins K, Muñoz F, Moser K, Cerecer-Callu P, Raab F, et al. Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study. Int J Tuberc Lung Dis 2015;19:1057–64. 10.5588/ijtld.14.092326260824
  99. Sinkou H, Hurevich H, Rusovich V, Zhylevich L, Falzon D, de Colombani P, et al. Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience. Eur Respir J 2017;49:1602049. 10.1183/13993003.02049-201628331042
  100. Hoffman JA, Cunningham JR, Suleh AJ, Sundsmo A, Dekker D, Vago F, et al. Mobile direct observation treatment for tuberculosis patients: a technical feasibility pilot using mobile phones in Nairobi, Kenya. Am J Prev Med 2010;39:78–80. 10.1016/j.amepre.2010.02.018 20537846
  101. Nguyen TA, Pham MT, Nguyen TL, Nguyen VN, Pham DC, Nguyen BH, Fox GJ. Video directly observed therapy to support adherence with treatment for tuberculosis in Vietnam: a prospective cohort study. Int J Infect Dis 2017;65:85–9. 10.1016/j.ijid.2017.09.02929030137
  102. Olano-Soler H, Thomas D, Joglar O, Rios K, Torres-Rodríguez M, Duran-Guzman G, Chorba T. Notes from the field: use of asynchronous video directly observed therapy for treatment of tuberculosis and latent tuberculosis infection in a long-term-care facility – Puerto Rico, 2016–17. MMWR Morb Mortal Wkly Rep 2017;66:1386–7. 10.15585/mmwr.mm6650a5 29267264
  103. Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974;15:443–53. 10.1002/cpt19741554434597226
  104. Rogers WH. Regression standard errors in clustered samples. Stata Tech Bull 1993;13:19–23.
  105. Volmink J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev 2007;4:CD003343. 10.1002/14651858.CD003343.pub3
  106. Tian JH, Lu ZX, Bachmann MO, Song FJ. Effectiveness of directly observed treatment of tuberculosis: a systematic review of controlled studies. Int J Tuberc Lung Dis 2014;18:1092–8. 10.5588/ijtld.13.086725189558
  107. Moodley R, Godec TR, STREAM Trial Team. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev 2016;25:29–35. 10.1183/16000617.0080-2015 26929418
  108. White PJ, Abubakar I. Improving control of tuberculosis in low-burden countries: insights from mathematical modeling. Front Microbiol 2016;7:394. 10.3389/fmicb.2016.0039427199896
  109. White P, Jit M, Stagg H, Pimpin L, Choi Y, Mugwagwa T. Economic Analysis of Identifying and Managing Tuberculosis in Hard to Reach Groups: Homeless and Prison Populations. 2011. URL: www.nice.org.uk/guidance/ph37/documents/economic-analysis-of-identifying-and-managing-tuberculosis-in-hard-to-reach-groups-homeless-and-prison-populations-2 (accessed 3 May 2019).
  110. Pareek M, Abubakar I, White PJ, Garnett GP, Lalvani A. Tuberculosis screening of migrants to low-burden nations: insights from evaluation of UK practice. Eur Respir J 2011;37:1175–82. 10.1183/09031936.0010581021071474
  111. Greater London Authority. CHAIN Annual Report 2016–17. London: Greater London Authority; 2018. URL: https://data.london.gov.uk/dataset/chain-reports (accessed 25 September 2020).
  112. Cabinet Office. Rough Sleeping: Report by the Social Exclusion Unit (Command Paper). London: Cabinet Office; 1998.
  113. Salomon JA, Lloyd-Smith JO, Getz WM, Resch S, Sánchez MS, Porco TC, Borgdorff MW. Prospects for advancing tuberculosis control efforts through novel therapies. PLOS Med 2006;3:e273. 10.1371/journal.pmed.003027316866578
  114. The National Tuberculosis Institute B. Tuberculosis in a rural population of South India: a five-year epidemiological study. Bull World Health Organ 1974;51:473–88.4549498
  115. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010;137:952–68. 10.1378/chest.09-235020022968
  116. White PJ. Imperial College – LTBI Treatment Report. NICE. 2015.
  117. Cudahy P, Shenoi SV. Diagnostics for pulmonary tuberculosis. Postgrad Med J 2016;92:187–93. 10.1136/postgradmedj-2015-13327827005271
  118. Taegtmeyer M, Beeching NJ, Scott J, Seddon K, Jamieson S, Squire SB, et al. The clinical impact of nucleic acid amplification tests on the diagnosis and management of tuberculosis in a British hospital. Thorax 2008;63:317–21. 10.1136/thx.2007.08381618024540
  119. Steingart KR, Schiller I, Horne DJ, Pai M, Boehme CC, Dendukuri N. Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev 2014;1:CD009593. 10.1002/14651858.CD009593.pub3
  120. Abubakar I, White P, Jit M, Pimpin L, Aldridge R, Tamne S, et al. Evaluation of the Find and Treat Service for the Control of Tuberculosis Amongst Hard to Reach Groups. London: Department of Health; 2011.
  121. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini IM, Dye C, Halloran ME. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci USA 2009;106:13980–5. 10.1073/pnas.090172010619666590
  122. NICE. Developing NICE Guidelines: the Manual. Process and Methods Guide. Manchester; NICE; 2014.
  123. Pareek M, Bond M, Shorey J, Seneviratne S, Guy M, White P, et al. Community-based evaluation of immigrant tuberculosis screening using interferon γ release assays and tuberculin skin testing: observational study and economic analysis. Thorax 2013;68:230–9. 10.1136/thoraxjnl-2011-20154222693179
  124. Drobniewski F, Cooke M, Jordan J, Casali N, Mugwagwa T, Broda A, et al. Systematic review, meta-analysis and economic modelling of molecular diagnostic tests for antibiotic resistance in tuberculosis. Health Technol Assess 2015;19(34). 10.3310/hta19340
  125. NHS England. Guide to the Enhanced Tariff Option for 2015/16. 2016. URL: https://webarchive.nationalarchives.gov.uk/20161103233943tf_/https://www.england.nhs.uk/resources/pay-syst/tariff-guide/ (accessed 3 May 2019).
  126. Kind P, Dolan P, Gudex C, Williams A. Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 1998;316:736–41. 10.1136/bmj.316.7133.7369529408
  127. Kruijshaar ME, Lipman M, Essink-Bot ML, Lozewicz S, Creer D, Dart S, et al. Health status of UK patients with active tuberculosis. Int J Tuberc Lung Dis 2010;14:296–302. 10.1164/ajrccm-conference.2009.179.1_MeetingAbstracts.A141620132620
← DiscussionAcknowledgements →

Attribution. Alistair Story; Elizabeth Garber; Robert W Aldridge; Catherine M Smith; Joe Hall; Gloria Ferenando et al. (2020). Management and control of tuberculosis control in socially complex groups: a research programme including three RCTs. NIHR Journals Library. Copyright © Queen’s Printer and Controller of HMSO 2020. This work was produced by Story et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK. Licensed under CC BY 4.0. NCBI Bookshelf NBK563462. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support